The NPPA (National Pharmaceutical Pricing Authority) had capped the rates of bare metal stents at INR 7,260 and INR 29,600 for drug-eluting stents and biodegradable stents to provide affordable healthcare to needy middle-class peoples. This is a price drop of about 85% from what is commercially offered before price capping.
A coronary stent is a spring-like metal tool that is exercised to open blocked arteries. The government has further added stent in the National List of Essential Medicines.
Earlier the Stent Prices in India is very high for instance a bare metal stent costs Rs 30 to 45 thousand whereas the drug-eluting stents cost between 80,000 to 1.5 lakh & biodegradable stents cost around 1.8 to 2 lakhs. The drug- eluting stents frame approximately 90 to 95% of the market and are inserted into ailing coronary arteries where they discharge drugs to avert cell proliferation.
According to NPPA, unethical and immense markups are charged at each step in the distribution and supply chain of coronary stents. As a result unreasonable and exorbitant prices are charged by doctors from patients, which drive patients towards monetary desolation.
After the price capping of essential medicine multinational health care firms like Medtronic India Pvt. Ltd and Abbott Healthcare Pvt. Ltd has filed the application to the NPPA to withdraw some high-end coronary stents from the Indian Health Care Market.
As they allege that this Price Capping of Essential Medicine is commercially unviable but the NPPA has rejected their applications. Several other health care companies are also trying hard to obstruct the government’s move to cap stents prices in India as it would upset their margins.
While, several cardiologists had welcomed the step taken by NPPA, but they have also shown a fear about quality getting compromised in the long run they also think that it may block new innovations and limit admittance to first-rate medicinal care.
This Price Capping of Essential Medicine has offered major assistance to lakhs of cardiac patients who are enforced to give incredibly high amounts for the device.
Apart from this, the government has also announced the price capping of essential medicines required by asthma patients as well as the government has issued various other Health Care Policies to provide inexpensive healthcare to general peoples; one of them is Generic Medicine facility.
Generic medicines are making a big impact on consumers as they are true alternatives to high charging branded medicines. Generic medicines are similar to brand-name medicines in safety, effectiveness and significance.
Yet these medicines are normally sold at lesser rates compare to branded medicines. These medicines have the same amount of ingredients as a branded medicine contains.
Consumers can buy these medicines via generic pharmacies or they can buy these medicines online. Some site on internet like HealthKartPlus.com, MyDawaai.com etc aid in improving general information of branded and Generic Medicines
Finally, we can consider the recent set of steps taken by the Indian Government as a great move towards composing easy and affordable health care for all. Furthermore, we expect from our government to carry out several other Health Care Policies to provide benefit to the massive population of India.